This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
Efficacy & SafetyAboutEfficacy & SafetyPatient SupportAboutAboutCommitment to the GH CommunityIndication & DosingIndication & DosingAdultsChildren

Menu

Close

Efficacy & SafetyAdultAdult Growth Hormone DeficiencyChildrenSmall for Gestational AgeTurner SyndromePrader-Willi SyndromeChronic Renal Insufficiency
Pediatric Growth Hormone Deficiency
Idiopathic Short Stature
DevicesPenPen PresentationHow to Use the PenGoQuickGoQuick PresentationHow to Use GoQuickPatient SupportPatient SupportGroAssistBranded Patient Information LeafletsEducational SupportEducational SupportPrescribing InformationWebinarsEventsMaterialsVideos

Children

Genotropin® is a GH therapy indicated for GHD1

  

The dosage and administration schedule should be individualised. The injection should be given subcutaneously and the site varied to prevent lipoatrophy.

  

Growth disturbance due to insufficient secretion of GH in children

  

Generally, a dose of 0.025 to 0.035 mg/kg body weight per day (0.7-1.0 mg/m² body surface area per day) is recommended. Even higher doses have been used. Where childhood-onset GHD persists into adolescence, treatment should be continued to achieve full somatic development
(e.g. body composition and bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score >−1 (i.e. standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period.

  

PWS for the improvement of growth and body composition in children

   

Generally, a dose of 0.035 mg/kg body weight per day (1.0 mg/m2 body surface area per day) is recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.

   

Growth disturbance due to TS

   

A dose of 0.045 to 0.050 mg/kg body weight per day (1.4 mg/m² body surface area per day) is recommended.

   

Growth disturbance in chronic renal insufficiency

   

A dose of 0.045 to 0.050 mg/kg body weight per day (1.4 mg/m² body surface area per day) is recommended. Higher doses can be needed if growth velocity is too low. A dose correction can be needed after 6 months of treatment.

   

Growth disturbance in short children born SGA

   

A dose of 0.035 mg/kg body weight per day (1 mg/m² body surface area per day) is usually recommended until the final height is reached (see Section 5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below +1. Treatment should be discontinued if the height velocity is <2 cm/year and, if confirmation is required, bone age is >14 years (girls) or >16 years (boys), corresponding to the closure of the epiphyseal growth plates.

   

Dosage Recommendations in Pediatric Patients

   

   

Adapted from Genotropin. Local product document. 2022. LPDSOM052020.

   

   

GH, growth hormone; GHD, growth hormone deficiency; PWS, Prader-Willi syndrome; SDS, standard deviation score; SGA, small for gestational age; TS, Turner syndrome.

   

Reference:

Genotropin. Local product document. Pfizer; 2022. Version LPDSOM052020.
Indication
mg/kg body weight
dose per day
mg/m2 body surface area dose per day
Growth hormone deficiency
in children
0.025 - 0.035 0.7 - 1.0
Prader-Willi syndrome in
children
0.035 1.0
Turner syndrome 0.045 - 0.050 1.4
Chronic renal insuffciency 0.045 - 0.050 1.4
Children born small for
gestational age
0.035 1.0

   

PP-GEN-IND-0678 July 2022

Scroll left to view table
Scroll left to view table
Scroll left to view table
Indication & Dosing
Devices

Simplicity and flexibility in administration1

Learn moreLoading
Patient Support

Multiple support material

Learn moreLoading
Educational Support

Review the upcoming events

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-GEN-IND-0678

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​